North Carolina Biotechnology Center

Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.

Baebies, Inc. manufactures screening and pediatric testing equipment for newborn babies. The company manufactures SEEKER, a newborn screening laboratory solution that performs multiple assays at the same time and quantitatively measures the activity of lysosomal enzymes using one punch from a newborn dried blood spot specimen. It also manufactures FINDER, a near-patient testing equipment that allows pediatric testing. The company serves hospitals and public health labs. Baebies, Inc. was incorporated in 2013 and is based in Durham, North Carolina.

Delivering cost effective biosimilars by developing disruptive technologies, advanced analytics and state-of-the-art manufacturing facility. Being the most desired Biotech company to work for by creating an unparalleled work culture. Broadening the footprint of their innovative technologies through strategic global alliances.

Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.

Plakous Therapeutics, Inc. produces in situ restorative and regenerative healing products. The company offers products, such as Protego-PD, is an orally delivered acellular biotherapeutic developed from post-delivery placentas. It provides allografts, which contain and deliver cytokines and growth factors remaining in the human placenta after the delivery. Plakous Therapeutics, Inc. was incorporated in 2016 and is based in Winston-Salem, North Carolina.

TregTherapeutics is a preclinical stage company focused on the treatment and possible cure of multiple sclerosis. The T lymphocyte is a key component in the acquired immune system, and a subset of T cells, the T-regulator cell (known as the Treg), plays an instrumental role in the control and regulation of the immune response. Named in recognition of the vital functions this cell executes, TregTherapeutics Inc. is focused on developing a tolerogenic vaccine for the treatment and possible cure of multiple sclerosis. The corporation is a North Carolina-based preclinical-stage company whose proprietary technology is based upon an exclusive license granted by East Carolina University. The technology is a transformative platform that utilizes a novel vaccine approach that harnesses the power of Tregs to dramatically alter patient outcomes in response to autoimmune disease.

Emergo Therapeutics is a pharmaceutical startup that develops treatment options for flu-like illnesses. It is focused on developing drugs to modulate inflammatory cytokines and improve the functioning of the immune system in various potential indications, starting with infectious diseases. Emergo’s therapeutic interventions are focused on reducing the production of inflammatory cytokines from mast cells. Emergo is headquartered in Durham, North Carolina.

The University of North Carolina at Chapel Hill is the non-profit organisation based in North Carolina, United States. The foundation is an educational institution that offers graduate and undergraduate degrees in arts, sciences, dentistry, education, medicine, nursing, pharmacy and law.

Jenken Biosciences is a specialty pharmaceutical company dedicated to the development and commercialization of first-in-class small molecules as TLR4 antagonists. TLR4 (Toll-Like Receptor 4) is a transmembrane protein, a key mediator of inflammatory responses, and a member of TLR family which are mainstays of the innate immune system. Recently, TLR4 has attracted considerable clinical attention and is the subject of a number of published studies on inflammation associated with chronic liver disease, inflammatory bowel disease, cancer, and diabetes, as well as organ damage to the kidney and lung. The Company's drug development strategy is to reduce time-to-market and to lower risk and development costs by re-profiling approved drugs. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapies of chronic liver disease, inflammatory bowel disease, rheumatoid arthritis, and diabetes, as well as organ damage to the kidney and the lung.

Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

Duke University is a private research university in Durham, North Carolina. Home of the Blue Devils, Duke University has about 15,000 undergraduate and graduate students and a world-class faculty helping to expand the frontiers of knowledge. The university has a strong commitment to applying knowledge in service to society, both near its North Carolina campus and around the world.

BioAesthetics was founded in 2015 as a Tulane University spin-out with the mission to improve reconstruction options for breast cancer patients after they undergo mastectomies. The BioAesthetics’ initial product is a tissue-engineered nipple-areolar complex (NAC). This product will be provided to plastic and reconstructive surgeons as an off-the-shelf ready, acellular, NAC graft. During the breast reconstruction phase, after a mastectomy, the surgeon would engraft the NAC graft in position onto the patient’s reconstructed breast. The patient’s body would then use this NAC graft as a building frame to regenerate their own NAC. This patent-pending product is currently in the pre-clinical phase.

Chiesi USA is a pharmaceuticals company specializing in pharmaceutical research & development services.

Arrevus, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for orphan diseases. Its product pipeline includes ARV-1801, a oral dosing regimen and formulation of fusidic acid for the treatment of pulmonary exacerbations in cystic fibrosis; ARV-1907, an inhaled formulation of fusidic acid for the treatment of persistent staphylococcus aureus lung infections in cystic fibrosis patients; ARV-1502, an engineered inhibitor of bacterial DnaK for cancer treatment; and ARV-1802, a leptin receptor antagonist for cancer treatment. The company was incorporated in 2015 and is headquartered in Raleigh, North Carolina.

Cereius, Inc. is a privately owned, pre-clinical stage company developing novel approaches to treating sold tumor brain metastasis. Cereius’ novel radiolabeling chemistries increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targeting agents.

The University of North Carolina at Chapel Hill is the non-profit organisation based in North Carolina, United States. The foundation is an educational institution that offers graduate and undergraduate degrees in arts, sciences, dentistry, education, medicine, nursing, pharmacy and law.

InnAVasc Medical, Inc., a medical device company, designs and develops products for vascular access for hemodialysis. Its technology includes Bullet Proof Vascular Access Graft, an arteriovenous graft that incorporates two multilayer cannulation chambers that are resistant to posterior and sidewall needle penetration and injury. InnAVasc Medical, Inc. was incorporated in 2013 and is based in Durham, North Carolina.

Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

CasTag Biosciences specializes in cell biology and regenerative medicine, focusing on revolutionizing the speed of endogenously protein analysis. The company aims to accelerate scientific discovery by offering tools that allow scientists to study novel genes in any experimental model.

Panacea Biomatx offers its customers with nutritional supplements that are according to each person’s gender, age, and weight. Customers are able to personalize their mix by choosing a flavor. Panacea Biomatx was founded by Edison Hudson and Staton Noel in January 2013. It is based in Durham, North Carolina.

Plakous Therapeutics, Inc. produces in situ restorative and regenerative healing products. The company offers products, such as Protego-PD, is an orally delivered acellular biotherapeutic developed from post-delivery placentas. It provides allografts, which contain and deliver cytokines and growth factors remaining in the human placenta after the delivery. Plakous Therapeutics, Inc. was incorporated in 2016 and is based in Winston-Salem, North Carolina.

Higgs Boson Health (HBH), a leading digital health company empowering all people undergoing acute interventional or surgical procedures to live healthier lives.

Cereius, Inc. is a privately owned, pre-clinical stage company developing novel approaches to treating sold tumor brain metastasis. Cereius’ novel radiolabeling chemistries increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targeting agents.

Lindy Biosciences is a development-stage protein therapeutic formulations company. Our core technology produces spherical, dense, stable particles of a therapeutic protein. These protein particles are ideal for long-term storage, or for non-standard formulations such as suspension formulations (for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release), or dry powder pulmonary delivery.​

BiomedInnovations is a medical device company that makes precision air and fluid flow devices, including products for lung ventilators and ex-vivo organ and tissue perfusion.

North Carolina State University is an educational institution that offers graduate and undergraduate programs. The university offers academic qualifications in engineering, agriculture, life sciences, textiles and design, natural resources, and management through 106 bachelor’s degrees, 104 master’s degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The University of North Carolina’s 17 campuses extend from the state’s mountains to the coast. More than 220,000 students are enrolled at 16 universities and the NC School of Science and Mathematics, the country’s first public residential high school for gifted students. North Carolina State University is one of the eight universities with a presence at the North Carolina Research Campus, where it operates a research and education organization devoted to food crops. In March 2008, the university also launched the University Sustainability Office in order to address environmental concerns on campus. North Carolina State University was founded on March 7, 1987.

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured, multiple sclerosis and similar patient populations. By combining novel pharmaceutical agents with drug delivery technology, Dignify Therapeutics will redefine the treatment of these disorders and restore the dignity of voluntary excretory function for these patients. The company was founded in 2013 and is headquartered in Raleigh, North Carolina.

Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury.

North Carolina State University is an educational institution that offers graduate and undergraduate programs. The university offers academic qualifications in engineering, agriculture, life sciences, textiles and design, natural resources, and management through 106 bachelor’s degrees, 104 master’s degrees, 61 doctoral degrees, and a Doctor of Veterinary Medicine. The University of North Carolina’s 17 campuses extend from the state’s mountains to the coast. More than 220,000 students are enrolled at 16 universities and the NC School of Science and Mathematics, the country’s first public residential high school for gifted students. North Carolina State University is one of the eight universities with a presence at the North Carolina Research Campus, where it operates a research and education organization devoted to food crops. In March 2008, the university also launched the University Sustainability Office in order to address environmental concerns on campus. North Carolina State University was founded on March 7, 1987.

Aniluxx Biotechnology is a development stage biopharmaceutical company with a mission to improve companion animal health and well-being. The Company’s strategy is to translate its deep pipeline of topically formulated therapeutics, predicated on compounds that have already been identified as safe and effective in humans, into therapies for dogs, cats, and horses, that are easy to apply, virtually unnoticeable, and absent the harsh side effects of systemic medicines.

Monoclonal antibodies make up an effective and rapidly growing class of drugs. They are also critical research tools and essential for the development of many new diagnostics. Isolere Bio was co-founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.

Full investment portfolio: Debt Securities: 3.16% International Mutual Funds: 3.02% Equity Mutual Funds: 5.30% Domestic Stocks: 0.05% Hedge Funds: 2.06% Private Equity Limited Partnerships: 0.52% Other-Private Distressed Debt LP: 0.02% Investments as a Position in an External Investment Pool: -Short-Term Investment Fund: 85.04% - UNC Investment Fund:0.84% Founded in 1907, East Carolina University is a non-profit organisation based in the United States. The foundation is an educational institution that offers graduate, postgraduate, and doctoral programs in health sciences, medicine and business.

Drive Therapeutics is a new biotechnology company that strives to improve treatment for retinal diseases.

Duke BioRepository & Precision Pathology Center (BRPC), Duke’s largest human tissue biobank. BRPC stores samples from consented patients for use in research.

Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.

Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

Monoclonal antibodies make up an effective and rapidly growing class of drugs. They are also critical research tools and essential for the development of many new diagnostics. Isolere Bio was co-founded with the vision of simplifying and streamlining the purification of biotherapeutics to improve global access to these important drugs.

Redbud Labs is a microfluidic chip manufacturer. They are pioneering a new category of consumable components with MXR, the world’s first fully modular microfluidic mixer. World-class biotechnology firms use MXR to boost assay performance.Redbud Labs leverages MEMS technology conceived in Professor Richard Superfine’s research group at the University of North Carolina at Chapel Hill. They combine their breakthrough platform with deep scientific expertise to develop elegant solutions to the toughest microfluidic challenges.

The University of North Carolina Wilmington, the state's coastal university, is dedicated to the integration of teaching and mentoring with research and service. University of North Carolina Wilmington, commitment to student engagement, creative inquiry, critical thinking, thoughtful expression and responsible citizenship is expressed in our baccalaureate and master's programs, as well as doctoral programs in areas of expertise that serve state needs. Our culture reflects our values of diversity and globalization, ethics and integrity, and excellence and innovation.

UNC Charlotte is North Carolina's urban research university. It leverages its location in the state's largest city to offer internationally competitive programs of research and creative activity, exemplary undergraduate, graduate and professional programs, and a focused set of community engagement initiatives. UNC Charlotte maintains a particular commitment to addressing the cultural, economic, educational, environmental, health, and social needs of the greater Charlotte region.

Baebies, Inc. manufactures screening and pediatric testing equipment for newborn babies. The company manufactures SEEKER, a newborn screening laboratory solution that performs multiple assays at the same time and quantitatively measures the activity of lysosomal enzymes using one punch from a newborn dried blood spot specimen. It also manufactures FINDER, a near-patient testing equipment that allows pediatric testing. The company serves hospitals and public health labs. Baebies, Inc. was incorporated in 2013 and is based in Durham, North Carolina.

Baebies, Inc. manufactures screening and pediatric testing equipment for newborn babies. The company manufactures SEEKER, a newborn screening laboratory solution that performs multiple assays at the same time and quantitatively measures the activity of lysosomal enzymes using one punch from a newborn dried blood spot specimen. It also manufactures FINDER, a near-patient testing equipment that allows pediatric testing. The company serves hospitals and public health labs. Baebies, Inc. was incorporated in 2013 and is based in Durham, North Carolina.

Dualogics is a biotechnology company housed at the University of North Carolina at Chapel Hill. Dualogics uses a proprietary bispecific antibody technology to create bispecific antibody products with superior properties compared to alternative methods. Our goal is to collaborate with academic and industrial partners to develop and test a suite of multifunctional therapies and reagents.

​ Apie Therapeutics develop and commercialize novel Apelin Receptor biased agonist drug therapies, activating the Apelinergic System focused on the promising therapy targets of the Apelinergic System.

IMMvention Therapeutix, Inc. “IMMune Intervention for Auto-Inflammatory Diseases” IMMvention Therapeutix is focused on improving the lives of patients with auto-inflammatory diseases of huge unmet needs. The company is discovering and developing novel disease modifying therapies that inhibit the inflammation caused by activation of inflammasomes. The Company’s differentiation is its novel product pipeline powered by the intellectual capital of its team and a platform to discover small molecule inhibitors of **multiple** inflammasome receptors. The current 1st generation *single* receptor inflammasome inhibition approaches of other companies (such as IFM/Novartis, Nodthera, Inflazome etc.) are expected to be ineffective/suboptimal against diseases where **multiple** inflammasomes are activated. The Company’s initial target diseases are rare auto-inflammatory diseases (e.g. Bullous Pemphigoid, a blistering disease). The Company was co-founded in 2017 by pioneering scientists in the fields of immunology and innate immunity from the School of Medicine and Eshelman School of Pharmacy at the University of North Carolina-Chapel Hill. This includes, Dr. Jenny Ting who is preeminent scientific leader in fields of immunology, innate immunity and inflammasomes. IMMvention has been funded to date by NIH SBIR grants/contracts, North Carolina Biotechnology Center and Pharma collaborations. The company raise its first venture funding to progress its novel small molecule preclinical therapeutics pipeline to the clinic for treating rare auto-inflammatory diseases.

PRA International is one of the world's leading global clinical research organizations, conducting clinical trials in more than 85 countries across six continents. PRA provides outsourced clinical services across all phases of pharmaceutical and biotech drug development. Through its 30+ years of experience, PRA has developed the operational and therapeutic expertise to provide high quality, global service while maintaining their differentiating PERSONAL ELEMENT of commitment to excellence.